MwanzoDCTH • NASDAQ
add
Delcath Systems Inc
Bei iliyotangulia
$ 9.64
Bei za siku
$ 9.55 - $ 9.81
Bei za mwaka
$ 8.12 - $ 18.23
Thamani ya kampuni katika soko
343.60M USD
Wastani wa hisa zilizouzwa
1.16M
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Sep 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 20.56M | 83.60% |
Matumizi ya uendeshaji wa biashara | 18.33M | 69.40% |
Mapato halisi | elfu 830.00 | -55.47% |
Kiwango cha faida halisi | 4.04 | -75.72% |
Mapato kwa kila hisa | 0.02 | -66.67% |
EBITDA | elfu -324.00 | 73.55% |
Asilimia ya kodi ya mapato | -121.33% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Sep 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 88.91M | 535.45% |
Jumla ya mali | 124.30M | 292.33% |
Jumla ya dhima | 9.45M | -59.12% |
Jumla ya hisa | 114.85M | — |
hisa zilizosalia | 35.31M | — |
Uwiano wa bei na thamani | 2.97 | — |
Faida inayotokana na mali | -0.80% | — |
Faida inayotokana mtaji | -0.87% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Sep 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | elfu 830.00 | -55.47% |
Pesa kutokana na shughuli | 4.77M | 231.10% |
Pesa kutokana na uwekezaji | elfu -466.00 | 33.14% |
Pesa kutokana na ufadhili | 3.10M | 244.72% |
Mabadiliko halisi ya pesa taslimu | 7.39M | 214.30% |
Mtiririko huru wa pesa | 3.39M | -64.62% |
Kuhusu
Delcath Systems, Inc. is a publicly traded specialty pharmaceutical and medical device company, that develops percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to specific organs or regions of the body. Based in Queensbury, New York, the company has an intellectual property portfolio consisting of 28 patents worldwide. Delcath's Percutaneous Hepatic Perfusion is currently undergoing Phase II and Phase III trials against tumors in the liver. Delcath has a Cooperative Research and Development Agreement with the National Cancer Institute and has received Fast Track and a Special Protocol Assessment from the Food and Drug Administration for its use of melphalan in treating unresectable liver tumors. PHP, also known as the Delcath System, is tested for the treatment of metastatic melanoma in the liver and for primary liver cancer and metastatic hepatic malignancies from neuroendocrine cancers and adenocarcinomas, as well as patients with melanoma who previously received isolated perfusion. Chemotherapy is usually delivered intravenously, although a number of agents can be administered orally. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
1988
Makao Makuu
Tovuti
Wafanyakazi
96
